Biocad

This study tests a new drug called BCD-261 in people with moderate to severe ulcerative colitis who haven't responded well to other treatments. About 198 adults will receive either BCD-261 or a placebo to see if the drug can safely reduce symptoms and bring about remission. The g…

This study tests a new drug called BCD-261 in adults with moderate to severe active Crohn's disease who have not responded well to previous treatments. About 204 participants will receive either BCD-261 or a placebo to see if the drug can reduce symptoms and improve bowel inflamm…

This study tests a single dose of a new gene therapy called ANB-002 in adults with hemophilia B, a bleeding disorder. The goal is to see if it can prevent bleeding episodes as well as or better than regular factor IX injections. The trial involves 24 men aged 18 or older with sev…

This study tests a new medicine called BCD-281 for people with relapsing-remitting multiple sclerosis (RRMS). The goal is to see if it reduces brain lesions and relapses better than an existing drug. About 292 adults aged 18-55 with RRMS will take part. The trial is currently rec…

This study compares a new experimental drug, BCD-057, to the approved drug Humira in healthy men aged 18-45. The goal is to see how the body processes each drug, check for side effects, and measure immune reactions. Participants receive a single injection and are monitored for se…